Fred S. Apple, Ph.D
Dr. Apple is Professor of Laboratory Medicine in the Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, as well as Medical Director of Clinical Laboratories and the Clinical Chemistry and Toxicology Laboratories at Hennepin County Medical Center. In addition, he serves as the Forensic Toxicology Consultant to the Hennepin County Medical Examiner's Office. Dr. Apple instructs residents and fellows during their chemistry and toxicology rotations, as well as directs the Ph.D Clinical Chemistry Fellowship program. He is an established investigator at the Minneapolis Medical Research Foundation.
Dr. Apple received his undergraduate training at the Rensselaer Polytechnic Institute, in Troy, NY, and his doctorate at the University of Minnesota, Minneapolis, MN, in Bioorganic Biophysical Chemistry. He also received post-doctoral training in Clinical Chemistry at the Washington University School of Medicine, Barnes Hospital, in St. Louis, MO. Dr. Apple has been the recipient of numerous awards, including the 1983 Young Investigator Award from the International Society for Clinical Enzymology, the Swedish National Council for Sports Research Award, and AACC Outstanding Speaker Award (on multiple occasions). Dr. Apple has been a visiting professor at the Karolinska Institute in Stockholm, Sweden and Emory University School of Medicine, as well as a visiting lecturer in the Danish Society of Clinical Chemistry, in Copenhagen, Denmark. He is also active in numerous organizations, including the American Chemical Society, the American Association for Clinical Chemistry (previously on the Board of Directors and currently serving as Associate Editor of Clinical Chemistry), the American College of Sports Medicine, the International Society of Clinical Enzymology, the American Academy of Forensic Sciences, the Academy of Clinical Laboratory Physicians and Scientists, and the Society of Forensic Toxicology (SOFT). In addition, Dr. Apple is Chair of the IFCC, Committee Standardization of Markers of Cardiac Damage, a member of the United States Anti-Doping Agency Anti-Doping Review Board, and a member of the Global Task Force for Redefinition of Myocardial Infarction.
Dr Apple has been actively involved in NIH-, VA-, and industry-sponsored research studies involving application of cardiac, vascular inflammatory, and ischemic biomarkers for the detection of myocardial cell damage, ischemic, inflammatory and reperfusion injury, as well as risk stratification and outcomes research. Specifically, he has worked closely with numerous in-vitro diagnostic companies (Abbott, Roche, Bayer, Beckman Coulter, Dade Behring, Ortho Clinical Diagnostics, Response Biomedical, First Medical, Biosite, Mitsubishi, QuanTech, Amersham, Hybritech, Syva, and Sensera) over the past 20 years in designing protocols for proof of principal and analytical and clinical evaluations for PMA and 510k applications for FDA submission and approval for numerous cardiac biomarkers (CK-MB, myoglobin, glycogen phosphylase BB, cardiac troponin I and T, B-type natiruretic peptide, placental growth factor, unbound free fatty acids, ischemia modified albumin, and myeloperoxidase), and well as carrying out the laboratory studies and patient enrollment needs; all following appropriate IRB and HIPAA regulatory guidelines. Dr. Apple is the author of numerous publications, and has authored over 50 publications in the past six years alone.